NVCT — Nuvectis Pharma, Inc.
NVCT dilution and offerings
- Active shelf: S-3 (Aug 2026)
- Float: 20.6M shares
Dilution filings
🔔 Alert me if NVCT files an offering or S-3
$19.34+0.83%
Last close: · regular session
Last 60 sessions
Active shelf registration (S-3, Aug 2026). Float: 20.6M shares. Latest SEC filing: 8-K on Nov 4, 2026. NVCT closed at $19.34 (+0.83%) on Nov 3, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NVCT in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 13
- Website: https://www.nuvectis.com
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest SEC filings for NVCT
Latest NVCT news
- Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 Read article
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.